Related Experiment Video

Updated: Jul 16, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Does ORP150/HSP12A protect dopaminergic neurons against MPTP/MPP(+)-induced neurotoxicity?

Yasuko Kitao1, Tomohiro Matsuyama, Katsura Takano

  • 1Department of Neuroanatomy Kanazawa University Graduate School of Medical Science, Ishikawa, Japan. kitao@nanat.m.kanazawa-u.ac.jp

Antioxidants & Redox Signaling
|March 3, 2007
PubMed

Insights

The molecular chaperone ORP150/HSP12A protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP(+) neurotoxicity. This highlights the endoplasmic reticulum

Area of Science:

  • Neuroscience
  • Cell Biology
  • Biochemistry

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-4-phenylpyridinium (MPP(+)) are critical tools in modeling Parkinson disease (PD).
  • The endoplasmic reticulum (ER) plays a crucial role in cellular homeostasis and protein folding, particularly within vulnerable neuronal populations.

Purpose of the Study:

  • To investigate the role of the molecular chaperone ORP150/HSP12A, located in the ER, within the nigrostriatal system.
  • To determine if ORP150/HSP12A confers protection against MPTP/MPP(+)-induced neurotoxicity in dopaminergic cells and neurons.

Main Methods:

  • Utilized dopaminergic neuroblastoma SH-SY5Y cells for in vitro studies.
  • Examined dopaminergic neurons from the substantia nigra pars compacta (SNpc) in experimental models.

Main Results:

  • ORP150/HSP12A was identified as a significant molecular chaperone in the nigrostriatal pathway.
  • Observations suggest that ORP150/HSP12A provides a protective effect against MPTP/MPP(+)-induced neurotoxicity.

Conclusions:

  • The endoplasmic reticulum environment is vital for maintaining the integrity of nigrostriatal pathways.
  • ORP150/HSP12A emerges as a key factor in neuroprotection against MPTP/MPP(+)-induced damage relevant to Parkinson disease models.

More Related Videos

The 6-hydroxydopamine Rat Model of Parkinson's Disease08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...